Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9242008 | 0.86 | NLN (0.41) | NAMPTRAB9ACYP1A2NPC1 | |
| SCHEMBL27913327 | 0.84 | CYP3A4 (0.33) | CYP1A2SLC7A5 | |
| SCHEMBL23572977 | 0.82 | LTA4H (0.47) | — | |
| SCHEMBL21794922 | 0.82 | LTA4H (0.47) | — | |
| SCHEMBL23572978 | 0.82 | LTA4H (0.47) | — | |
| Hippuric Acid SCHEMBL29157716 | 0.81 | KDM4E (0.42) | CYP1A2PKMSLC7A5 | |
| SCHEMBL29616794 | 0.80 | CSK (0.33) | — | |
| SCHEMBL2445252 | 0.80 | EGFR (0.50) | ALDH1A1 | |
| SCHEMBL23572993 | 0.80 | EGFR (0.50) | ALDH1A1 | |
| SCHEMBL6115780 | 0.79 | POLB (0.32) | ALDH1A1SMN1; SMN2RAB9ACYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999024461-A1 | CLOSTRIDIAL TOXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-05-20 | — | — | WO | claimed |
| US-9448231-B2 | Application of quantum dots for nuclear staining | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20120219948-A1 | APPLICATION OF QUANTUM DOTS FOR NUCLEAR STAINING | VENTANA MEDICAL SYSTEMS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20040067492-A1 | Reverse transcription on microarrays | MERGEN LIMITED | 2004-04-08 | — | — | US | disclosed |
| WO-1999024461-A1 | CLOSTRIDIAL TOXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219948-A1 | APPLICATION OF QUANTUM DOTS FOR NUCLEAR STAINING | DNASE1, DNASE1L3, MKI67 | NAMPT 2408/4885ALDH1A1 3765/4885SMN1; SMN2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.